182 related articles for article (PubMed ID: 19299010)
1. Magnetically targeted thrombolysis with recombinant tissue plasminogen activator bound to polyacrylic acid-coated nanoparticles.
Ma YH; Wu SY; Wu T; Chang YJ; Hua MY; Chen JP
Biomaterials; 2009 Jul; 30(19):3343-51. PubMed ID: 19299010
[TBL] [Abstract][Full Text] [Related]
2. Polyacrylic acid-coated nanoparticles loaded with recombinant tissue plasminogen activator for the treatment of mice with ischemic stroke.
Huang L; Wang J; Huang S; Siaw-Debrah F; Nyanzu M; Zhuge Q
Biochem Biophys Res Commun; 2019 Aug; 516(2):565-570. PubMed ID: 31235258
[TBL] [Abstract][Full Text] [Related]
3. Recombinant Tissue Plasminogen Activator-conjugated Nanoparticles Effectively Targets Thrombolysis in a Rat Model of Middle Cerebral Artery Occlusion.
Deng J; Mei H; Shi W; Pang ZQ; Zhang B; Guo T; Wang HF; Jiang XG; Hu Y
Curr Med Sci; 2018 Jun; 38(3):427-435. PubMed ID: 30074208
[TBL] [Abstract][Full Text] [Related]
4. Thrombolysis induced by intravenous administration of plasminogen activator in magnetoliposomes: dual targeting by magnetic and thermal manipulation.
Liu CH; Hsu HL; Chen JP; Wu T; Ma YH
Nanomedicine; 2019 Aug; 20():101992. PubMed ID: 30981818
[TBL] [Abstract][Full Text] [Related]
5. Preparation of Peptide and Recombinant Tissue Plasminogen Activator Conjugated Poly(Lactic-Co-Glycolic Acid) (PLGA) Magnetic Nanoparticles for Dual Targeted Thrombolytic Therapy.
Chen HA; Ma YH; Hsu TY; Chen JP
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32294917
[TBL] [Abstract][Full Text] [Related]
6. Bioconjugation of recombinant tissue plasminogen activator to magnetic nanocarriers for targeted thrombolysis.
Yang HW; Hua MY; Lin KJ; Wey SP; Tsai RY; Wu SY; Lu YC; Liu HL; Wu T; Ma YH
Int J Nanomedicine; 2012; 7():5159-73. PubMed ID: 23055728
[TBL] [Abstract][Full Text] [Related]
7. Construction and evaluation of Fe₃O₄-based PLGA nanoparticles carrying rtPA used in the detection of thrombosis and in targeted thrombolysis.
Zhou J; Guo D; Zhang Y; Wu W; Ran H; Wang Z
ACS Appl Mater Interfaces; 2014 Apr; 6(8):5566-76. PubMed ID: 24693875
[TBL] [Abstract][Full Text] [Related]
8. Magnetically controlled release of recombinant tissue plasminogen activator from chitosan nanocomposites for targeted thrombolysis.
Chen JP; Liu CH; Hsu HL; Wu T; Lu YJ; Ma YH
J Mater Chem B; 2016 Apr; 4(15):2578-2590. PubMed ID: 32263281
[TBL] [Abstract][Full Text] [Related]
9. Targeted Thrombolysis with Magnetic Nanotherapeutics: A Translational Assessment.
Lin ML; Wu SY; Chen JP; Lu YC; Jung SM; Wey SP; Wu T; Ma YH
Pharmaceutics; 2024 Apr; 16(5):. PubMed ID: 38794257
[TBL] [Abstract][Full Text] [Related]
10. Effect of recombinant plasminogen activator timing on thrombolysis in a novel rat embolic stroke model.
Ma Y; Li L; Niu Z; Song J; Lin Y; Zhang H; Du G
Pharmacol Res; 2016 May; 107():291-299. PubMed ID: 27038532
[TBL] [Abstract][Full Text] [Related]
11. Retention assessment of magnetic nanoparticles in rat arteries with micro-computed tomography.
Tu SJ; Wu SY; Wang FS; Ma YH
Phys Med Biol; 2014 Mar; 59(5):1271-81. PubMed ID: 24556757
[TBL] [Abstract][Full Text] [Related]
12. Effects of a TAFI-inhibitor combined with a suboptimal dose of rtPA in a murine thromboembolic model of stroke.
Durand A; Chauveau F; Cho TH; Kallus C; Wagner M; Boutitie F; Maucort-Boulch D; Berthezène Y; Wiart M; Nighoghossian N
Cerebrovasc Dis; 2014; 38(4):268-75. PubMed ID: 25401979
[TBL] [Abstract][Full Text] [Related]
13. Targeted delivery of tissue plasminogen activator by binding to silica-coated magnetic nanoparticle.
Chen JP; Yang PC; Ma YH; Tu SJ; Lu YJ
Int J Nanomedicine; 2012; 7():5137-49. PubMed ID: 23055726
[TBL] [Abstract][Full Text] [Related]
14. Hemostatic activation and outcome after recombinant tissue plasminogen activator therapy for acute ischemic stroke.
Tanne D; Macko RF; Lin Y; Tilley BC; Levine SR;
Stroke; 2006 Jul; 37(7):1798-804. PubMed ID: 16763191
[TBL] [Abstract][Full Text] [Related]
15. Polyacrylic acid-coated iron oxide nanoparticles for targeting drug resistance in mycobacteria.
Padwal P; Bandyopadhyaya R; Mehra S
Langmuir; 2014 Dec; 30(50):15266-76. PubMed ID: 25375643
[TBL] [Abstract][Full Text] [Related]
16. Human recombinant tissue-plasminogen activator (alteplase): why not use the 'human' dose for stroke studies in rats?
Haelewyn B; Risso JJ; Abraini JH
J Cereb Blood Flow Metab; 2010 May; 30(5):900-3. PubMed ID: 20216551
[TBL] [Abstract][Full Text] [Related]
17. Sequentially Site-Specific Delivery of Thrombolytics and Neuroprotectant for Enhanced Treatment of Ischemic Stroke.
Xu J; Wang X; Yin H; Cao X; Hu Q; Lv W; Xu Q; Gu Z; Xin H
ACS Nano; 2019 Aug; 13(8):8577-8588. PubMed ID: 31339295
[TBL] [Abstract][Full Text] [Related]
18. Thrombolytic therapy in canine pulmonary embolism. Comparative effects of urokinase and recombinant tissue plasminogen activator.
Prewitt RM; Hoy C; Kong A; Gu SA; Greenberg D; Cook R; Chan SM; Ducas J
Am Rev Respir Dis; 1990 Feb; 141(2):290-5. PubMed ID: 2105682
[TBL] [Abstract][Full Text] [Related]
19. Differences in clot preparation determine outcome of recombinant tissue plasminogen activator treatment in experimental thromboembolic stroke.
Niessen F; Hilger T; Hoehn M; Hossmann KA
Stroke; 2003 Aug; 34(8):2019-24. PubMed ID: 12843350
[TBL] [Abstract][Full Text] [Related]
20. Plasminogen activator-coated nanobubbles targeting cellbound β2-glycoprotein I as a novel thrombus-specific thrombolytic strategy.
Macor P; Durigutto P; Argenziano M; Smith-Jackson K; Capolla S; Di Leonardo V; Marchbank K; Tolva VS; Semeraro F; Ammollo CT; Colucci M; Cavalli R; Meroni P; Tedesco F
Haematologica; 2023 Jul; 108(7):1861-1872. PubMed ID: 36172817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
